8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 7, 2026·SEC
Supernus Pharmaceuticals, Inc.(SUPN)Earnings, Financials & Key Ratios
SUPN•NASDAQ
Price updated Jun 19, 2026
AboutSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.Show more
- Revenue$719M+8.6%
- EBITDA$55M-66.3%
- Net Income-$39M-152.2%
- EPS (Diluted)-0.68-151.5%
- Gross Margin89.63%+1.6%
- EBITDA Margin7.61%-68.9%
- Operating Margin-5.13%-141.6%
- Net Margin-5.36%-148.0%
- ROE-3.68%-148.7%
SUPN Key Insights
Supernus Pharmaceuticals, Inc. (SUPN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak 3Y average ROE of 1.3%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SUPN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SUPN Price & Volume
Supernus Pharmaceuticals, Inc. (SUPN) stock price & volume — 10-year historical chart
Loading chart...
SUPN Growth Metrics
Supernus Pharmaceuticals, Inc. (SUPN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.41%
5 Years6.68%
3 Years2.52%
TTM16.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-146.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-146.09%
Return on Capital
10 Years13.95%
5 Years2.88%
3 Years1.34%
Last Year-3.37%
SUPN Recent Earnings
Supernus Pharmaceuticals, Inc. (SUPN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.59+110.7%
$0.28
Rev
$208M+7.7%
$193M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.92+228.6%
$0.28
Rev
$212M+8.4%
$195M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.01+23.2%
$0.82
Rev
$192M-1.3%
$195M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.91+93.6%
$0.47
Rev
$165M-1.7%
$168M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.59vs $0.28+110.7% | $208Mvs $193M+7.7% |
| Q1 2026 | Feb 24, 2026 | $0.92vs $0.28+228.6% | $212Mvs $195M+8.4% |
| Q4 2025 | Nov 4, 2025 | $1.01vs $0.82+23.2% | $192Mvs $195M-1.3% |
| Q3 2025 | Aug 5, 2025 | $0.91vs $0.47+93.6% | $165Mvs $168M-1.7% |
Based on last 12 quarters of dataView full earnings history →
SUPN Peer Comparison
Supernus Pharmaceuticals, Inc. (SUPN) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 HRMY | 1.93B | 33.28 | 12.28 | 21.51% | 16.2% | 17.19% | 0.28 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare SUPN vs Peers
Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SUPN Income Statement
Supernus Pharmaceuticals, Inc. (SUPN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 302.24M | 408.9M | 392.75M | 520.4M | 579.77M | 667.24M | 607.52M | 661.82M | 718.95M | 776.83M |
Revenue Growth % | 40.57% | 35.29% | -3.95% | 32.5% | 11.41% | 15.09% | -8.95% | 8.94% | 8.63% | 16.29% |
Cost of Goods Sold | 15.21M | 15.36M | 16.66M | 52.46M | 75.06M | 87.22M | 83.78M | 77.91M | 74.56M | 82.19M |
COGS % of Revenue | 5.03% | 3.76% | 4.24% | 10.08% | 12.95% | 13.07% | 13.79% | 11.77% | 10.37% | - |
Gross Profit | 287.02M▲ 0% | 393.54M▲ 37.1% | 376.1M▼ 4.4% | 467.94M▲ 24.4% | 504.71M▲ 7.9% | 580.02M▲ 14.9% | 523.74M▼ 9.7% | 583.91M▲ 11.5% | 644.39M▲ 10.4% | 694.64M▲ 0% |
Gross Margin % | 94.97% | 96.24% | 95.76% | 89.92% | 87.05% | 86.93% | 86.21% | 88.23% | 89.63% | 89.42% |
Gross Profit Growth % | 41.38% | 37.11% | -4.43% | 24.42% | 7.86% | 14.92% | -9.7% | 11.49% | 10.36% | - |
Operating Expenses | 187.48M | 249.1M | 227.52M | 294.24M | 418.69M | 533.89M | 529.01M | 502.25M | 681.25M | 737.24M |
OpEx % of Revenue | 62.03% | 60.92% | 57.93% | 56.54% | 72.22% | 80.02% | 87.08% | 75.89% | 94.76% | - |
Selling, General & Admin | 137.91M | 159.89M | 158.43M | 200.68M | 304.76M | 377.22M | 336.36M | 335.78M | 485.56M | 520.79M |
SG&A % of Revenue | 45.63% | 39.1% | 40.34% | 38.56% | 52.56% | 56.53% | 55.37% | 50.74% | 67.54% | - |
Research & Development | 49.58M | 89.21M | 69.1M | 75.96M | 90.47M | 74.55M | 91.59M | 108.8M | 106.23M | 118.75M |
R&D % of Revenue | 16.4% | 21.82% | 17.59% | 14.6% | 15.6% | 11.17% | 15.08% | 16.44% | 14.78% | - |
Other Operating Expenses | 0 | 0 | 0 | 17.6M | 23.46M | 82.12M | 101.06M | 57.67M | 89.46M | 4M |
Operating Income | 99.54M▲ 0% | 144.44M▲ 45.1% | 148.57M▲ 2.9% | 173.7M▲ 16.9% | 86.03M▼ 50.5% | 46.12M▼ 46.4% | -5.27M▼ 111.4% | 81.67M▲ 1649.9% | -36.86M▼ 145.1% | -42.6M▲ 0% |
Operating Margin % | 32.93% | 35.33% | 37.83% | 33.38% | 14.84% | 6.91% | -0.87% | 12.34% | -5.13% | -5.48% |
Operating Income Growth % | 83.6% | 45.11% | 2.86% | 16.91% | -50.47% | -46.39% | -111.42% | 1649.93% | -145.14% | - |
EBITDA | 107.67M | 151.51M | 158.8M | 191.84M | 118.62M | 131.67M | 79.59M | 162.08M | 54.7M | 28.58M |
EBITDA Margin % | 35.63% | 37.05% | 40.43% | 36.86% | 20.46% | 19.73% | 13.1% | 24.49% | 7.61% | 3.68% |
EBITDA Growth % | 90.18% | 40.71% | 4.81% | 20.81% | -38.16% | 11% | -39.55% | 103.64% | -66.25% | -81.51% |
D&A (Non-Cash Add-back) | 8.13M | 7.06M | 10.22M | 18.14M | 32.59M | 85.54M | 84.86M | 80.41M | 91.56M | 71.18M |
EBIT | 99.54M | 144.44M | 170.19M | 192.4M | 96.6M | 67.81M | 5.18M | 97.87M | -49.03M | -54.77M |
Net Interest Income | 1.08M | -4.27M | -1.08M | -5.05M | -12.85M | 14.62M | 8.04M | 16.2M | 13.25M | 8.83M |
Interest Income | 2.65M | 13.84M | 21.62M | 18.7M | 10.57M | 21.69M | 10.45M | 16.2M | 13.25M | 8.83M |
Interest Expense | 1.57M | 18.11M | 22.71M | 23.75M | 23.42M | 7.07M | 2.42M | 0 | 0 | 0 |
Other Income/Expense | 1.08M | -4.27M | -1.08M | -5.05M | -12.85M | 14.62M | 8.04M | 16.2M | -12.17M | -6.55M |
Pretax Income | 100.62M▲ 0% | 140.18M▲ 39.3% | 147.49M▲ 5.2% | 168.65M▲ 14.3% | 73.17M▼ 56.6% | 60.74M▼ 17.0% | 2.77M▼ 95.4% | 97.87M▲ 3434.5% | -49.03M▼ 150.1% | -49.15M▲ 0% |
Pretax Margin % | 33.29% | 34.28% | 37.55% | 32.41% | 12.62% | 9.1% | 0.46% | 14.79% | -6.82% | -6.33% |
Income Tax | 43.33M | 29.18M | 34.43M | 41.7M | 19.75M | 32K | 1.45M | 24M | -10.48M | -20.13M |
Effective Tax Rate % | 43.07% | 20.82% | 23.35% | 24.72% | 26.99% | 0.05% | 52.47% | 24.53% | 21.37% | 40.96% |
Net Income | 57.28M▲ 0% | 110.99M▲ 93.8% | 113.06M▲ 1.9% | 126.95M▲ 12.3% | 53.42M▼ 57.9% | 60.71M▲ 13.6% | 1.32M▼ 97.8% | 73.86M▲ 5512.8% | -38.55M▼ 152.2% | -29.02M▲ 0% |
Net Margin % | 18.95% | 27.14% | 28.79% | 24.39% | 9.21% | 9.1% | 0.22% | 11.16% | -5.36% | -3.74% |
Net Income Growth % | -37.2% | 93.76% | 1.86% | 12.29% | -57.92% | 13.64% | -97.83% | 5512.84% | -152.19% | -146.87% |
Net Income (Continuing) | 57.28M | 110.99M | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | 73.86M | -38.55M | -29.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.08▲ 0% | 2.05▲ 89.8% | 2.10▲ 2.4% | 2.36▲ 12.4% | 0.98▼ 58.5% | 1.04▲ 6.1% | 0.02▼ 97.7% | 1.32▲ 5469.6% | -0.68▼ 151.5% | -0.50▲ 0% |
EPS Growth % | -38.64% | 89.81% | 2.44% | 12.38% | -58.47% | 6.12% | -97.72% | 5469.62% | -151.52% | -146.09% |
EPS (Basic) | 1.13 | 2.13 | 2.16 | 2.41 | 1.01 | 1.13 | 0.02 | 1.34 | -0.68 | - |
Diluted Shares Outstanding | 53.3M | 54.1M | 53.82M | 53.69M | 54.36M | 61.68M | 55.51M | 55.96M | 56.45M | 57.65M |
Basic Shares Outstanding | 50.76M | 51.99M | 52.41M | 52.62M | 53.1M | 53.67M | 54.54M | 55.1M | 56.45M | 57.65M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SUPN Balance Sheet
Supernus Pharmaceuticals, Inc. (SUPN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 228.45M | 493.49M | 472.64M | 630.42M | 601.59M | 734.15M | 493.11M | 686.07M | 644.18M | 731.58M |
Cash & Short-Term Investments | 140.04M | 356.02M | 347.07M | 422.53M | 339.68M | 461.33M | 254.87M | 453.61M | 308.67M | 384.24M |
Cash Only | 100.3M | 192.25M | 181.38M | 288.64M | 203.43M | 93.12M | 75.05M | 69.33M | 128.45M | 184.87M |
Short-Term Investments | 39.74M | 163.77M | 165.69M | 133.89M | 136.25M | 368.21M | 179.82M | 384.28M | 180.22M | 199.37M |
Accounts Receivable | 65.59M | 102.92M | 87.33M | 140.88M | 148.93M | 165.5M | 144.16M | 142.08M | 187.8M | 182.18M |
Days Sales Outstanding | 79.21 | 91.87 | 81.16 | 98.81 | 93.76 | 90.53 | 86.61 | 78.36 | 95.34 | 80.12 |
Inventory | 16.3M | 25.66M | 26.63M | 48.33M | 85.96M | 91.54M | 77.41M | 54.29M | 82.39M | 87.06M |
Days Inventory Outstanding | 391.12 | 609.89 | 583.39 | 336.24 | 417.99 | 383.08 | 337.24 | 254.37 | 403.3 | 325.15 |
Other Current Assets | 6.52M | 8.89M | 0 | 0 | 0 | 15.78M | 16.68M | 36.09M | 65.33M | 78.09M |
Total Non-Current Assets | 196.01M | 484.32M | 687.64M | 873.68M | 1.09B | 968.36M | 784.56M | 682M | 808.47M | 769.14M |
Property, Plant & Equipment | 5.12M | 4.09M | 17.07M | 37.82M | 16.95M | 15.17M | 13.53M | 11.54M | 10.53M | 10.04M |
Fixed Asset Turnover | 58.98x | 99.85x | 23.01x | 13.76x | 34.19x | 43.98x | 44.90x | 57.32x | 68.27x | 73.51x |
Goodwill | 0 | 0 | 0 | 77.91M | 117.52M | 117.02M | 117.02M | 117.02M | 124.88M | 120.67M |
Intangible Assets | 36.02M | 31.37M | 24.84M | 364.34M | 784.69M | 702.46M | 599.89M | 521.91M | 569.46M | 549.71M |
Long-Term Investments | 133.64M | 418.8M | 591.77M | 350.36M | 119.17M | 93.9M | 16.62M | 0 | 0 | 0 |
Other Non-Current Assets | 389K | 380K | 21.89M | 43.25M | 49.23M | 39.81M | 37.51M | 31.53M | 65.25M | 57.9M |
Total Assets | 424.46M▲ 0% | 977.81M▲ 130.4% | 1.16B▲ 18.7% | 1.5B▲ 29.6% | 1.69B▲ 12.3% | 1.7B▲ 0.8% | 1.28B▼ 25.0% | 1.37B▲ 7.1% | 1.45B▲ 6.2% | 1.5B▲ 0% |
Asset Turnover | 0.71x | 0.42x | 0.34x | 0.35x | 0.34x | 0.39x | 0.48x | 0.48x | 0.49x | 0.54x |
Asset Growth % | 37.11% | 130.36% | 18.66% | 29.63% | 12.3% | 0.79% | -24.95% | 7.08% | 6.18% | 28.37% |
Total Current Liabilities | 123M | 161.35M | 160.59M | 245.11M | 315.38M | 687.96M | 290.2M | 292.4M | 338.17M | 373.93M |
Accounts Payable | 6.84M | 3.19M | 10.14M | 6.15M | 9.33M | 10.54M | 1.96M | 4.59M | 2.68M | 0 |
Days Payables Outstanding | 164.18 | 75.94 | 222.18 | 42.77 | 45.37 | 44.12 | 8.56 | 21.49 | 13.1 | 132.68 |
Short-Term Debt | 4.28M | 2.18M | 0 | 0 | 0 | 401.97M | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 287K | -2.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 17.03M | 22.99M | 14.47M | 55.99M | 93.04M | 54.95M | 77.08M | 68.56M | 98.72M | 373.93M |
Current Ratio | 1.86x | 3.06x | 2.94x | 2.57x | 1.91x | 1.07x | 1.70x | 2.35x | 1.90x | 1.96x |
Quick Ratio | 1.72x | 2.90x | 2.78x | 2.37x | 1.63x | 0.93x | 1.43x | 2.16x | 1.66x | 1.72x |
Cash Conversion Cycle | 306.15 | 625.82 | 442.37 | 392.28 | 466.38 | 429.49 | 415.3 | 311.24 | 485.53 | 272.59 |
Total Non-Current Liabilities | 33.98M | 363.44M | 404.27M | 514.14M | 557.92M | 128.35M | 65.96M | 39.94M | 52.76M | 49.99M |
Long-Term Debt | 22.26M | 329.46M | 345.17M | 361.75M | 379.25M | 0 | 0 | 0 | 0 | 30.27M |
Capital Lease Obligations | 0 | 0 | 30.44M | 48.81M | 41.3M | 36M | 33.2M | 27.38M | 30.36M | 86.17M |
Deferred Tax Liabilities | 14.96M | 31.46M | 0 | 35.22M | 85.36M | 49.81M | 24.96M | 4.96M | 0 | 0 |
Other Non-Current Liabilities | 10.58M | 33.97M | 28.66M | 68.36M | 52.02M | 42.54M | 7.8M | 7.6M | 22.4M | 19.72M |
Total Liabilities | 156.98M | 524.79M | 564.85M | 759.24M | 873.3M | 816.3M | 356.16M | 332.34M | 390.93M | 423.92M |
Total Debt | 26.54M | 329.46M | 378.44M | 414.32M | 427.03M | 444.76M | 41.53M | 34.27M | 40.98M | 30.27M |
Net Debt | -73.76M | 137.21M | 197.05M | 125.69M | 223.59M | 351.64M | -33.53M | -35.06M | -87.47M | -154.6M |
Debt / Equity | 0.10x | 0.73x | 0.64x | 0.56x | 0.52x | 0.50x | 0.05x | 0.03x | 0.04x | 0.03x |
Debt / EBITDA | 0.25x | 2.17x | 2.38x | 2.16x | 3.60x | 3.38x | 0.52x | 0.21x | 0.75x | 1.06x |
Net Debt / EBITDA | -0.69x | 0.91x | 1.24x | 0.66x | 1.88x | 2.67x | -0.42x | -0.22x | -1.60x | -5.41x |
Interest Coverage | 63.48x | 7.98x | 7.50x | 8.10x | 4.12x | 9.59x | 2.15x | - | - | - |
Total Equity | 267.48M▲ 0% | 453.02M▲ 69.4% | 595.43M▲ 31.4% | 744.86M▲ 25.1% | 815.85M▲ 9.5% | 886.2M▲ 8.6% | 921.52M▲ 4.0% | 1.04B▲ 12.4% | 1.06B▲ 2.5% | 1.08B▲ 0% |
Equity Growth % | 39.49% | 69.37% | 31.43% | 25.1% | 9.53% | 8.62% | 3.98% | 12.39% | 2.51% | 22.32% |
Book Value per Share | 5.02 | 8.37 | 11.06 | 13.87 | 15.01 | 14.37 | 16.60 | 18.51 | 18.81 | 18.68 |
Total Shareholders' Equity | 267.48M | 453.02M | 595.43M | 744.86M | 815.85M | 886.2M | 921.52M | 1.04B | 1.06B | 1.08B |
Common Stock | 51K | 52K | 53K | 53K | 53K | 54K | 55K | 56K | 57K | 58K |
Retained Earnings | -26.82M | 86.49M | 199.55M | 326.5M | 379.92M | 481.25M | 482.56M | 556.43M | 517.88M | 515.58M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -747K | -3.16M | 7.42M | 8.97M | 1.54M | -3.21M | -593K | -189K | -44K | -255K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SUPN Cash Flow Statement
Supernus Pharmaceuticals, Inc. (SUPN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 114.64M | 128.99M | 143.13M | 138.4M | 127.13M | 116.83M | 111.08M | 171.95M | 47.33M | 83.26M |
Operating CF Margin % | 37.93% | 31.54% | 36.44% | 26.59% | 21.93% | 17.51% | 18.29% | 25.98% | 6.58% | - |
Operating CF Growth % | 71.59% | 12.51% | 10.96% | -3.3% | -8.14% | -8.1% | -4.91% | 54.79% | -72.47% | -88.77% |
Net Income | 57.28M | 110.99M | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | 73.86M | -38.55M | -29.02M |
Depreciation & Amortization | 8.13M | 7.06M | 6.66M | 18.14M | 32.59M | 85.54M | 84.86M | 80.41M | 90.03M | 164.28M |
Stock-Based Compensation | 8.43M | 11.29M | 14.85M | 16.56M | 17.91M | 17.57M | 26.76M | 27.75M | 33.05M | 56.86M |
Deferred Taxes | 21.22M | -4.17M | -5.83M | 568K | -4.99M | -26.32M | -25.71M | -20.14M | 5.21M | 1.31M |
Other Non-Cash Items | -4.14M | 8.54M | 13.79M | 12.69M | 24.62M | 3.57M | 33M | 12.11M | 32.75M | 13.32M |
Working Capital Changes | 23.71M | -4.73M | 613K | -36.52M | 3.57M | -24.24M | -9.14M | -2.05M | -75.16M | -89.06M |
Change in Receivables | -24.06M | -35.86M | 15.75M | -34.61M | 3.87M | -16.37M | 18.77M | 2.08M | -22.3M | -13.12M |
Change in Inventory | 497K | -9.36M | -969K | -10.12M | -14.58M | -17.86M | 6.11M | 15.81M | -7.5M | -10.42M |
Change in Payables | -620K | -3.58M | 6.96M | 8.27M | 18.18M | -19.16M | -36.29M | -15.02M | -24.57M | -28.45M |
Cash from Investing | -86.42M | -413.48M | -157.92M | -34.7M | -81.91M | -216.66M | 268.73M | -189.87M | 4.11M | -52.43M |
Capital Expenditures | -2.03M | -844K | -2.74M | -3.45M | -2.04M | -412K | -551K | -725K | -1.34M | -1.92M |
CapEx % of Revenue | 0.67% | 0.21% | 0.7% | 0.66% | 0.35% | 0.06% | 0.09% | 0.11% | 0.19% | 0.25% |
Acquisitions | 0 | 0 | 0 | -313.54M | -311.69M | -14K | 0 | 0 | -293.09M | -293.09M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -11.15M | -809K | 1.35M | -241K | 12.89M | 14K | 0 | 9K | -439K | -348.93M |
Cash from Financing | 5.68M | 376.44M | 3.93M | 3.56M | -130.42M | -10.48M | -397.88M | 12.19M | 9.13M | 39.64M |
Debt Issued (Net) | 0 | 309.6M | 0 | -802K | -137.51M | 0 | -402.5M | 0 | 0 | 0 |
Equity Issued (Net) | 5.68M | 11.58M | 3.93M | 4.36M | 7.09M | 12.42M | 6.61M | 14.91M | 37.62M | 35.57M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 55.25M | 0 | 0 | 0 | -22.9M | -1.99M | -2.71M | -28.49M | 4.07M |
Net Change in Cash | 33.91M▲ 0% | 91.94M▲ 171.2% | -10.87M▼ 111.8% | 107.26M▲ 1087.0% | -85.21M▼ 179.4% | -110.31M▼ 29.5% | -18.07M▲ 83.6% | -5.72M▲ 68.3% | 60.57M▲ 1158.3% | 70.47M▲ 0% |
Free Cash Flow | 112.61M▲ 0% | 128.14M▲ 13.8% | 140.39M▲ 9.6% | 134.95M▼ 3.9% | 125.08M▼ 7.3% | 116.41M▼ 6.9% | 110.53M▼ 5.1% | 171.23M▲ 54.9% | 45.99M▼ 73.1% | 82.25M▲ 0% |
FCF Margin % | 37.26% | 31.34% | 35.75% | 25.93% | 21.57% | 17.45% | 18.19% | 25.87% | 6.4% | 10.59% |
FCF Growth % | 72.69% | 13.79% | 9.56% | -3.88% | -7.31% | -6.93% | -5.05% | 54.91% | -73.14% | -49.65% |
FCF per Share | 2.11 | 2.37 | 2.61 | 2.51 | 2.30 | 1.89 | 1.99 | 3.06 | 0.81 | 1.43 |
FCF Conversion (FCF/Net Income) | 2.00x | 1.16x | 1.27x | 1.09x | 2.38x | 1.92x | 84.41x | 2.33x | -1.23x | -2.83x |
Interest Paid | 134K | 1.34M | 2.52M | 2.52M | 2.52M | 2.52M | 1.95M | 0 | 0 | 0 |
Taxes Paid | 1.59M | 34.77M | 51.54M | 45.43M | 25.19M | 16.2M | 36.6M | 53.25M | 0 | 15.51M |
SUPN Key Ratios
Supernus Pharmaceuticals, Inc. (SUPN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 24.95% | 30.81% | 21.57% | 18.94% | 6.85% | 7.13% | 0.15% | 7.55% | -3.68% | -2.73% |
Return on Invested Capital (ROIC) | 49.85% | 27.64% | 16.12% | 15.67% | 6.76% | 3.04% | -0.37% | 6.49% | -2.8% | -3.38% |
Gross Margin | 94.97% | 96.24% | 95.76% | 89.92% | 87.05% | 86.93% | 86.21% | 88.23% | 89.63% | 89.42% |
Net Margin | 18.95% | 27.14% | 28.79% | 24.39% | 9.21% | 9.1% | 0.22% | 11.16% | -5.36% | -3.74% |
Debt / Equity | 0.10x | 0.73x | 0.64x | 0.56x | 0.52x | 0.50x | 0.05x | 0.03x | 0.04x | 0.03x |
Interest Coverage | 63.48x | 7.98x | 7.50x | 8.10x | 4.12x | 9.59x | 2.15x | - | - | - |
FCF Conversion | 2.00x | 1.16x | 1.27x | 1.09x | 2.38x | 1.92x | 84.41x | 2.33x | -1.23x | -2.83x |
Revenue Growth | 40.57% | 35.29% | -3.95% | 32.5% | 11.41% | 15.09% | -8.95% | 8.94% | 8.63% | 16.29% |
Related:SUPN Dividend History·SUPN Revenue History·SUPN Price History·SUPN P/E History·SUPN Financial Ratios·SUPN Institutional Holders
SUPN SEC Filings & Documents
Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)
SUPN Frequently Asked Questions
Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Supernus Pharmaceuticals, Inc. (SUPN) reported $776.8M in revenue for fiscal year 2025. This represents a 8639% increase from $8.9M in 2008.
Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 8.6% over the past year. This is steady growth.
Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $29.0M for fiscal year 2025.
Dividend & Returns
Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.
Supernus Pharmaceuticals, Inc. (SUPN) generated $82.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.